

GUILLAIN BARRE SYNDROME (GBS)

Done by : Malak Al-Tamimi Faculty of Medicine /Mutah uni



* Demyelinating Disorders

Central demyelinating disorders

Multiple sclerosis Acute disseminated encephalomyelitis(ADEM) Neuromyelitis optica Progressive multifocal leukoencephalopathy

peripheral demyelinating disorders

Guillain-Barré syndrome chronic inflammatory demyelinating polyneuropathy(CIDP)





Guillain-Barre Syndrome (GBS): Introduction

- Autoimmune demyelinating disorder that leads to progressive paralysis
- Most common cause of acute flaccid, neuromuscular paralysis Worldwide

Epidemiology:

- 0.4 to 2 cases per 100,000
- · Males slightly more affected than females



-> ACUTE PARALYTIC POLYNEUROPATHY

-> ACUTE PARALYTIC POLYNEUROPATHY









Possible Causes

- Influenza vaccine
 - 1 case per 1 million vaccinations
- Gastrointestinal and Respiratory Infections
 - Campylobacter infection (watery/bloody diarrhea)
 - Influenza infection
- Surgery
- Trauma



GBS: Pathophysiology

Immune-mediated process leading to neuropathy

- Occurs post-infection
- Appears related to molecular mimicry
- Ganglioside antibodies
- <u>Example</u>: Lipopolysaccharide on outer membrane of campylobacter jejuni resembles gangliosides of peripheral nerve membranes

GBS: Pathophysiology

Immune-mediated process leading to neuropathy

- Occurs post-infection
- Appears related to molecular mimicry
- Ganglioside antibodies
- Example: Lipopolysaccharide on outer membrane of campylobacter jejuni resembles gangliosides of peripheral nerve membranes









GBS: Other Clinical Features

Autonomic Dysfunction

- Blood pressure dysregulation
 - Orthostatic hypotension
- Urinary retention
- Cardiac arrythmias
- Sinus tachycardia
- Significant cause of morbidity and mortality

- Altered mental status
 - "Bickerstaff encephalitis"
- Dysphagia
- Facial nerve involvement
- Neurogenic pulmonary edema

Symptoms peak within approximately 2-3 weeks of onset Resolution of symptoms within 4-6 weeks Monophasic in nature



GBS: Diagnosis

Diagnosis:

- Clinical diagnosis
 - Diagnostic Criteria

Required:

1) Progressive, symmetric weakness of >1 limb

2) Hyporeflexia/Areflexia

- 3) Progression <4 weeks
- 4) Symmetric weakness

+ Supportive

+ Exclusion of Other Diagnoses

- EMG & Nerve conduction tests can be used to confirm/differentiate (conduction block, decreased F-wave, sural sparing)
- Lumbar puncture ("Albuminocytologic dissociation")
 - Normal WBC
 - Elevated CSF protein
 - These findings may not be present in all individuals



Guillain-Barr'e Syndrome

Three A's :

- Ascending paralysis
- Autonomic neuropathy
- Albuminocytologic dissociation

GBS: Clinical Variants

Miller-Fisher Syndrome

- Involves anti-GQ1B antibodies
- Triad of symptoms: 1) <u>A</u>cute <u>O</u>pthalmoplegia, 2) <u>A</u>reflexia, 3) <u>A</u>taxia
- Involves no weakness

Acute Inflammatory Demyelinating Polyneuropathy (AIDP)

- Most common variant
- · EMG partial motor conduction block

Pharyngeal-Cervical-Brachial Variant

· Primarily involves ptosis, pharyngeal, and neck and spreads to upper extremity muscles

Acute Motor Axonal Neuropathy (AMAN)

- Associated with C. jejuni infections
- Involves anti-GM1 antibodies
- Motor involvement only; normal reflexes
- More frequently occurs in Asian countries

Acute Motor-Sensory Axonal Neuropathy (AMSAN)

Associated with C. jejuni infections

GBS: Treatment

Treatment:

- Better to administer within 4 weeks of symptom onset (Best within 2 weeks)
- Intravenous Immunoglobulin (IVIG)
- Plasmapheresis
- Intubation due to risk of respiratory failure
- VTE prophylaxis (LMWH)
- Avoid steroid use

85% of patients recover and are able to independently ambulate However, 20% may still have residual morbidity

Thank you

